Ascent Advisors LLC Takes Position in VanEck Biotech ETF $BBH

Ascent Advisors LLC purchased a new position in shares of VanEck Biotech ETF (NASDAQ:BBH) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 59,450 shares of the company’s stock, valued at approximately $11,178,000. VanEck Biotech ETF makes up approximately 17.7% of Ascent Advisors LLC’s holdings, making the stock its biggest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Empowered Funds LLC acquired a new stake in VanEck Biotech ETF in the fourth quarter valued at $38,000. Flagship Harbor Advisors LLC bought a new position in VanEck Biotech ETF during the 4th quarter valued at $47,000. Allworth Financial LP grew its holdings in VanEck Biotech ETF by 255.0% during the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock worth $81,000 after acquiring an additional 306 shares in the last quarter. Huntington National Bank acquired a new position in VanEck Biotech ETF during the 4th quarter worth $132,000. Finally, Evelyn Partners Asset Management Ltd increased its position in shares of VanEck Biotech ETF by 16.9% in the 4th quarter. Evelyn Partners Asset Management Ltd now owns 941 shares of the company’s stock worth $178,000 after purchasing an additional 136 shares during the last quarter. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Performance

Shares of VanEck Biotech ETF stock opened at $209.28 on Thursday. The firm’s 50-day simple moving average is $190.26 and its 200-day simple moving average is $191.32. VanEck Biotech ETF has a 1 year low of $154.75 and a 1 year high of $212.54.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.